Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic Stem Cell Transplantation for Aggressive Sickle Cell Disease
NCT01499888Phase 2Active, not recruiting
- Sponsor
- University of Illinois Chicago
- Start
- Nov 2011
- Primary completion
- Sep 2028
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of alemtuzumab, sirolimus, allogeneic hematopoietic stem cells in sickle cell disease (SCD), sponsored by University of Illinois Chicago. Started Nov 2011; status: active, not recruiting.
02
Drugs
alemtuzumabsirolimusallogeneic hematopoietic stem cells
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT01499888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01499888.